新作坊

Believe it or not: how much can we rely on published data on potential drug targets?

摘要：

A recent report by Arrowsmith noted that the success rates for new development projects in Phase II trials have fallen from 28% to 18% in recent years, with insufficient efficacy being the most frequent reason for failure (Phase II failures: 2008–2010. Nature Rev. Drug Discov. 10, 328–329 (2011))1. This indicates the limitations of the predictivity of disease models and also that the validity of the targets being investigated is frequently questionable, which is a crucial issue to address if success rates in clinical trials are to be improved.[...]